Identification and Utilization of Antibacterial Agents


Overview

The technology provides a method of identifying the site of interaction between bacterial toxin and antitoxin polypeptides. The technique includes

a) Exposing toxin and antitoxin polypeptides of a toxin-antitoxin pair produced by the bacterial cell to a plurality of molecules; and
b) Identifying a molecule of the plurality of molecules capable of preventing or disrupting binding between the antitoxin and the toxin polypeptides. It thus enables to identify or design antibiotics which target this site of interaction and thus enable bacterial cell killing.

The technology also provides a technique of treating an infection of bacteria by preventing or disrupting binding between a toxin and antitoxin polypeptides of a toxin-antitoxin pair produced in the bacteria.

The technology also provides a pharmaceutical composition for treating an infection of bacteria through an effective amount of an agent capable of preventing or disturbing binding between a toxin and antitoxin polypeptide.

Primary Application of the Technology

Pharmaceutical industry

The Problem Solved by the Technology

Several well-known antibiotics commonly used in healthcare have become ineffective as microbes develop resistance to them. The rate of mutation does not reciprocate with the discovery of antibiotics. Infectious microbes have a remarkable ability to evolve, adapt and develop drug resistance in an unpredictable and dynamic way. Antibiotic resistance first became challenging shortly after Penicillin gained extensive use in the 1940s.

Antibiotics currently being used against bacterial pathogens include beta-lactams (e.g., Penicillin and Cephalosporin) and glycopeptides (e.g., Vancomycin and Teichoplanin), which act to inhibit the final step in peptidoglycan synthesis, quinolones, which inhibit bacterial DNA replication, inhibitors of bacterial RNA polymerase such as Rifampin, and aminoglycosides (e.g., Kanamycin and Gentamycin). Other well-known antibiotics include inhibitors of enzymes participating in production of tetrahydrofolate (e.g., Sulfonamides).

How the Technology Solves the Problem

The limitation can be realized effectively with this novel technology which can be used for suppress the resistant strain incidence.

Patent Granted

Technology available for Licensing

Copyright © 2012 SkyQuest Technology Group: Building Invention Economy



plugin by DynamicWP
#